The role of oxidized LDL in atherogenesis: Immunological response and anti-phospholipid antibodies

Annals of the New York Academy of Sciences

Volumn 811, Issue , 1997, Pages 88-99

  Witztum, Joseph L ^a   Hörkkö, Sohvi ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CARDIOLIPIN; CARDIOLIPIN ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID ANTIBODY;

ATHEROGENESIS; AUTOIMMUNITY; CONFERENCE PAPER; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; LIPID PEROXIDATION; MACROPHAGE; NONHUMAN;

EID: 0030853416     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1997.tb51992.x     Document Type: Conference Paper

References (27)

1. STEINBERG, D., S. PARTHASARATHY, T. E. CAREW, J. C. KHOO & J. L. WITZTUM. 1989. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320(14): 915-924.
2. WITZTUM, J. L. 1994. The oxidation hypothesis of atherosclerosis. Lancet 344(8925): 793-795.
3. GOLDSTEIN, J. L., Y. K. HO, S. K. BASU & M. S. BROWN. 1979. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl. Acad. Sci. USA 76(1): 333-337.
4. HENRIKSEN, T., E. M. MAHONEY & D. STEINBERG. 1981. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc. Natl. Acad. Sci. USA 78(10): 6499-6503.
5. STEINBRECHER, U. P., S. PARTHASARATHY, D. S. LEAKE, J. L. WITZTUM & D. STEINBERG. 1984. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc. Natl. Acad. Sci. USA 81(12): 3883-3887.
6. HEINECKE, J. W., H. ROSEN & A. CHAIT. 1984. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J. Clin. Invest. 74(5): 1890-1894.
7. HESSLER, J. R., A. L. ROBERTSON, JR. & G. M. CHISOLM, 3D. 1979. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 32(3): 213-229.
8. ENDEMANN, G., L. W. STANTON, K. S. MADDEN, C. M. BRYANT, R. T. WHITE & A. A. PROTTER. 1993. CD36 is a receptor for oxidized low density lipoprotein. J. Biol. Chem. 268(16): 11811-11816.
9. RAMPRASAD, M. P., W. FISCHER, J. L. WITZTUM, G. R. SAMBRANO, O. QUEHENBERGER & D. STEINBERG. 1995. The 94- to 97-kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and phosphatidylserine-rich liposomes is identical to macrosialin, the mouse homologue of human CD68. Proc. Natl. Acad. Sci. USA 92(21): 9580-9584.
10. ACTON, S. L., P. E. SCHERER, H. F. LODISH & M. KRIEGER. 1994. Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J. Biol. Chem. 269(33): 21003-21009.
11. SAMBRANO, G. R., S. PARTHASARATHY & D. STEINBERG. 1994. Recognition of oxidatively damaged erythrocytes by a macrophage receptor with specificity for oxidized low density lipoprotein. Proc. Natl. Acad. Sci. USA 91(8): 3265-3269.
12. BERLINER, J. A., M. NAVAB, A. M. FOGELMAN, J. S. FRANK, L. L. DEMER, P. A. EDWARDS, A. D. WATSON & A. J. LUSIS. 1995. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 91(9): 2488-2496.
13. WATSON, A. D., M. NAVAB, S. Y. HAMA, A. SEVANIAN, S. M. PRESCOTT, D. M. STAFFORINI, T. M. MCINTYRE, B. N. DU, A. M. FOGELMAN & J. A. BERLINER. 1995. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J. Clin. Invest. 95(2): 774-782.
14. HEERY, J. M., M. KOZAK, D. M. STAFFORINI, D. A. JONES, G. A. ZIMMERMAN, T. M. MCINTYRE & S. M. PRESCOTT. 1995. Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. J. Clin. Invest. 96(5): 2322-2330.
15. WITZTUM, J. L. & D. STEINBERG. 1991. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88(6): 1785-1792.
16. PENN, M. S. & G. M. CHISOLM. 1994. Oxidized lipoproteins, altered cell function and atherosclerosis. Atherosclerosis 108(Suppl): S21-29.
17. STEINBERG, D. 1995. Role of oxidized LDL and antioxidants in atherosclerosis. Adv. Exp. Med. Biol. 369: 39-48.
18. PALINSKI, W., M. E. ROSENFELD, S. YLÄ-HERTTUALA, G. C. GURTNER, S. S. SOCHER, S. W. BUTLER, S. PARTHASARATHY, T. E. CAREW, D. STEINBERG & J. L. WITZTUM. 1989. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. USA 86(4): 1372-1376.
19. YLÄ-HERTTUALA, S., W. PALINSKI, M. E. ROSENFELD, S. PARTHASARATHY, T. E. CAREW, S. BUTLER, J. L. WITZTUM & D. STEINBERG. 1989. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 84(4): 1086-1095.
20. SALONEN, J. T., S. YLÄ-HERTTUALA, R. YAMAMOTO, S. BUTLER, H. KORPELA, R. SALONEN, K. NYYSSONEN, W. PALINSKI & J. L. WITZTUM. 1992. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339(8798): 883-887.
21. WITZTUM, J. L. & W. PALINSKI. 1996. Autoimmunity to oxidized lipoproteins. In Immune Functions of the Vessel Wall. G. K. Hansson & P. Libby, Eds.: 159-172. Harwood Academic Publishers. London.
22. LIBBY, P. & G. K. HANSSON. 1991. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab. Invest. 64(1): 5-15.
23. STEMME, S. & G. K. HANSSON. 1994. Immune mechanisms in atherogenesis. Ann. Medicine 26(3): 141-146.
24. BRANCH, D. W., M. D. MITCHELL, E. MILLER, W. PALINSKI & J. L. WITZTUM. 1994. Pre-eclampsia and serum antibodies to oxidised low-density lipoprotein. Lancet 343(8898): 645-646.
25. HÖRKKÖ, S., E. MILLER, E. DUDL, P. REAVEN, L. K. CURTISS, N. J. ZVAIFLER, R. TERKELTAUB, S. S. PIERANGELI, D. W. BRANCH, W. PALINSKI & J. L. WITZTUM. 1996. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids: Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low-density lipoprotein. J. Clin. Invest. 98: 815-825.
26. PALINSKI, W., S. HÖRKKÖ, E. MILLER, U. P. STEINBRECHER, H. C. POWELL, L. K. CURTISS & J. L. WITZTUM. 1996. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apo E-deficient mice. Demonstration of epitopes of oxidized LDL in human plasma. J. Clin. Invest. 98: 800-814.
27. VAARALA, O., M. MÄNTTÄRI, V. MANNINEN, L. TENKANEN, M. PUURUNEN, K. AHO & T. PALOSUO. 1995. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 91(1): 23-27.